利用两项新型bOPV-IPV免疫程序随机对照试验数据探索2型脊髓灰质炎血清中和抗体与肠道免疫的关系
研究利用五国1640名婴儿的两项临床试验数据,分析bOPV-IPV混合或序贯程序中血清中和抗体与mOPV2攻击后病毒排出的关系。发现攻击时中和抗体滴度与排出指数终点呈统计学显著但微弱的负相关;即使抗体滴度很高也可能无法阻止病毒排出。
要点
- 攻击时中和抗体滴度与排出指数终点呈显著但微弱的负相关(p<.0001)。
核心结论
- 单独来看,IPV或bOPV/IPV混合或序贯免疫后攻击前中和抗体滴度与肠道免疫差异之间的弱关联不足以预测2型脊髓灰质炎肠道免疫;即使非常高的滴度也可能无法阻止病毒排出。
- 需要进一步研究以在全球OPV停用和仅使用IPV免疫的背景下确定肠道免疫的预测标志物。
研究设计与样本
- 在五个拉丁美洲国家开展的两项临床试验,纳入1640名婴儿,评估bOPV-IPV混合或序贯免疫程序。
- 利用血清中和抗体数据和口服mOPV2攻击后病毒排出(肠道免疫指标)数据进行分析。
- 采用广义相加模型和分位数回归模型分析攻击前中和抗体滴度与病毒排出的比例、持续时间和滴度(幅度)之间的关系。
主要发现
- 攻击时中和抗体滴度与排出指数终点(攻击后4次评估的粪便病毒滴度平均log10值)呈统计学显著(p<.0001)但微弱的关系。
- 总体呈微弱但显著的负相关,高中和抗体滴度与较低病毒排出率相关,亚组分析支持此效应以阐明国家间差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 中和抗体滴度与肠道免疫差异之间的关联微弱,单独不足以预测2型脊髓灰质炎肠道免疫。
- 即使非常高的中和抗体滴度也可能无法阻止病毒排出。
- 需要进一步研究以在全球OPV停用和仅使用IPV免疫的背景下确定肠道免疫的预测标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inactivated polio vaccine (IPV) is now the only source of routine type 2 protection. The relationship, if any, between vaccine-induced type 2 humoral and intestinal immunity is poorly understood. METHODS: Two clinical trials in five Latin American countries of mixed or sequential bOPV-IPV schedules in 1640 infants provided data on serum neutralizing antibodies (NAb) and intestinal immunity, assessed as viral shedding following oral mOPV2 challenge. Analyses with generalized additive and quantile regression models examined the relationships between prechallenge NAb titers and proportion, duration and titers (magnitude) of viral shedding. RESULTS: We found a statistically significant (p < .0001) but weak relationship between NAb titer at the time of mOPV2 challenge and the Shedding Index Endpoint, the mean log10 stool viral titer over 4 post-challenge assessments. Day 28 post-challenge shedding was 13.4% (8.1%, 18.8%) lower and the Day 21 post-challenge median titer of shed virus was 3.10 log10 (2.21, 3.98) lower for subjects with NAb titers at the ULOQ as compared with LLOQ on day of challenge. Overall, there was a weak but significant negative relationship, with high NAb titers associated with lower rates of viral shedding, an effect supported by subset analysis to elucidate between-country differences. CONCLUSIONS: Taken alone, the weak association between pre-challenge NAb titers following IPV or mixed/sequential bOPV/IPV immunization and differences in intestinal immunity is insufficient to predict polio type 2 intestinal immunity; even very high titers may not preclude viral shedding. Further research is needed to identify predictive markers of intestinal immunity in the context of global OPV cessation and IPV-only immunization.
引用
- Bandyopadhyay AS, Asturias EJ, O'Ryan M, et al. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine. 2017. PMID: 29150209. doi:10.1016/j.vaccine.2017.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。